Alentis Therapeutics
We develop breakthrough treatments for Claudin1-positive tumors and organ fibrosis
69 employees · est. 2019 · Allschwil, Switzerland
BioInvent International AB
BioInvent is translating cancer antibody biology into innovative immuno-oncology therapies.
139 employees · est. 1983 · Lund, Sweden
BioInvent International AB is the older company (2019 vs 1983).
Side-by-Side Comparison
| Metric | Alentis Therapeutics | BioInvent International AB |
|---|---|---|
| Founded | ||
| Founded | 2019 | 1983 older |
| Headquarters | ||
| Headquarters | Allschwil, Switzerland | Lund, Sweden |
| Employees | ||
| Employees | 69 | 139 |
| Industry | ||
| Industry | Biotechnology, Health and Wellness | Biotechnology, Health Care, Manufacturing |
| Funding Stage | ||
| Funding Stage | Series D | IPO |
| Total Funding | ||
| Total Funding | $364.50M | $5.64M |
| Funding Rounds | ||
| Funding Rounds | 4 | 6 |
| Services | ||
| Services | Development of anti-Claudin-1 ADCs, Clinical trials for monoclonal antibodies, Fibrosis study results publication, Leadership in therapeutic development | Antibody Discovery and Development, Clinical Programs in Immuno-oncology, Contract Manufacturing for Clinical Trials, Collaboration with Pharmaceutical Companies |
| Target Customers | ||
| Target Customers | Cancer patients, Patients with organ fibrosis, Healthcare professionals, Biotech investors | Cancer Patients, Biotech and Pharmaceutical Companies, Medical Professionals, Clinical Researchers |
| Taxonomy | ||
| Taxonomy | Claudin-1, Tumor Treatment, Organ Fibrosis, Antibody-drug Conjugates, Oncology, Liver Fibrosis, Kidney Fibrosis, Lung Fibrosis, Cancer Therapy, Clinical-stage Biotechnology, Multi-organ Fibrosis, Drug Discovery, Drug Development, Rare Diseases, Nephrology | Immuno-Oncology, Antibody Drug Development, Hematological Cancer Therapy, Solid Tumor Therapy, F.I.R.S.T™ Technology Platform, N-CoDeR™ Antibody Library, Clinical-Stage Biotech, Research Collaborations, License Agreements, Antibody Manufacturing, Process Development, Antibody Drug Discovery, Co-Development Agreements, Proprietary Antibody Selection |
| Website | ||
| Website | alentis.ch | bioinvent.com |
About Alentis Therapeutics
Alentis Therapeutics, founded in 2019, is a pioneering clinical-stage biotechnology company with a focus on developing breakthrough treatments for Claudin1-positive tumors and organ fibrosis. The company is based in the pharma-biotech hub of Basel, Switzerland. The company specializes in first-in-c...
About BioInvent International AB
BioInvent International AB, a clinical-stage biotech firm founded in 1983 and headquartered in Sweden, is pioneering the landscape of immuno-oncology therapies by translating cancer antibody biology into innovative treatments. Leveraging its unique F.I.R.S.T™ technology platform, the company is at t...
We will tell you when either one moves
BounceWatch watches Alentis Therapeutics and BioInvent International AB for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Alentis Therapeutics and BioInvent Internationa... — by email.
Frequently Asked Questions
Compare Alentis Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Alentis Therapeutics on 28 Jan 2026, and BioInvent International AB on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.